Mancini Anthony 4
4 · Revolution Medicines, Inc. · Filed Apr 29, 2026
Research Summary
AI-generated summary of this filing
Revolution Medicines (RVMD) Anthony Mancini Exercises Options and Sells Shares
What Happened
Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines (RVMD), exercised 3,120 stock options on April 27, 2026 by paying $33.62 per share (total cost $104,894). The same day he sold those 3,120 shares in multiple open‑market trades for aggregate proceeds of approximately $413,129 (three blocks at weighted average prices of $131.66, $132.88 and $134.34). The transactions were executed under a prearranged 10b5‑1 trading plan.
Key Details
- Transaction date: 2026-04-27 (filed 2026-04-29). Filing appears timely.
- Exercise: 3,120 shares acquired at $33.62 each, total $104,894 (Form 4 code M).
- Sales: 1,671 shares @ $131.66 (≈ $220,007); 1,049 shares @ $132.88 (≈ $139,388); 400 shares @ $134.34 (≈ $53,734). Total sales ≈ $413,129. Sales executed in multiple trades; reported prices are weighted averages (see footnotes for trade price ranges).
- Derivative reporting: a corresponding derivative disposition of 3,120 units was reported at $0.00 (standard reporting for option exercise/cancellation).
- Holdings note: Filing includes 54,400 Restricted Stock Units (RSUs) referenced in footnote; total shares beneficially owned after the transactions are not specified in the excerpt.
- Plan/footnotes: Transactions were made pursuant to a 10b5‑1 plan adopted Dec 24, 2025. Vesting schedule for the option (1/4 after 1 year from Apr 1, 2025; monthly thereafter over 4 years) is noted.
Context
This was an option exercise followed by same‑day open‑market sales (effectively a cashless exercise), not an open‑market purchase. Exercises coupled with immediate sales are common for executives realizing proceeds from vested awards and are different from open‑market purchases, which some investors view as a stronger bullish signal. The transactions were governed by a 10b5‑1 plan, which means the sales were pre‑scheduled.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1][F2]2026-04-27$33.62/sh+3,120$104,894→ 57,520 total - Sale
Common Stock
[F1][F3][F2]2026-04-27$131.66/sh−1,671$220,007→ 55,849 total - Sale
Common Stock
[F1][F4][F2]2026-04-27$132.88/sh−1,049$139,388→ 54,800 total - Sale
Common Stock
[F1][F5][F2]2026-04-27$134.34/sh−400$53,734→ 54,400 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F6]2026-04-27−3,120→ 109,230 totalExercise: $33.62Exp: 2035-03-31→ Common Stock (3,120 underlying)
Footnotes (6)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025.
- [F2]Includes 54,400 Restricted Stock Units.
- [F3]This transaction was executed in multiple trades at prices ranging from $131.08 to $132.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $132.37 to $133.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This transaction was executed in multiple trades at prices ranging from $134.04 to $134.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F6]Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.